Risk factors for cancer in patients with myositis

被引:1
作者
Zsuzsanna, Szankai [1 ]
Nagy-Vincze Melinda [1 ]
Bodoki Levente [1 ]
Jakab Andras [2 ]
Zoe Betteridge [3 ]
Danko Katalin [1 ]
机构
[1] Debreceni Egyet, Klin Kozpont, Belgyogyaszati Int, Klin Immunol Tanszek, Debrecen, Hungary
[2] Med Univ Vienna, Dept Biomed Imaging & Image Guided Therapy, Vienna, Austria
[3] Univ Bath, Royal Natl Hosp Rheumat Dis, Bath BA2 7AY, Avon, England
关键词
myositis; dermatomyositis; polymyositis; cancer-associated myositis; clinical immunology; antibodies; DERMATOMYOSITIS; POLYMYOSITIS; AUTOANTIBODY; MALIGNANCY; MYOPATHY; DISEASE;
D O I
10.1556/OH.2014.29984
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Idiopathic inflammatory myopathies are systemic autoimmune diseases characterized by progressive proximal muscle weakness. Cancer-associated myositis represents the worst prognostic group within this heterogeneous disease. Aim: The aim of this study was to reveal factors which increase the risk factors for association of cancerous disease in patients with myositis. Furthermore, the authors explored the most common types of associated malignancies in their patients with myositis and characterize the clinical findings in a sub-group of anti-p155/140 positive patients. Method: In this retrospective study, myositis patients with and without associated cancer were analysed (32 and 64 patients, respectively). In addition, anti-p155/140 positive and negative groups were compared, irrespective to the presence of associated malignancies. Results: The risk for associated malignancy was higher in patients with severe muscle and skin symptoms and those with dermatomyositis. Furthermore, increased risk for malignancy was noted in the presence of particular skin symptoms and the absence of systemic symptoms. The anti-p155/140 antibody was proved to be a feasible marker of an independent clinical sub-group which overlapped clinical characteristics with cancer-associated myositis. Conclusions: These results may help the identification of patients with myositis with a higher risk for associated malignancy.
引用
收藏
页码:1437 / 1444
页数:8
相关论文
共 21 条
[1]  
Andras Csilla, 2002, Magy Onkol, V46, P253
[2]   Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis [J].
Azuma, Kohei ;
Yamada, Hidehiro ;
Ohkubo, Michiko ;
Yamasaki, Yoshioki ;
Yamasaki, Masaomi ;
Mizushima, Machiko ;
Ozaki, Shoichi .
MODERN RHEUMATOLOGY, 2011, 21 (02) :178-183
[3]  
Bielsa I, 2009, ACTAS DERMO-SIFILOGR, V100, P182
[4]   POLYMYOSITIS AND DERMATOMYOSITIS .1. [J].
BOHAN, A ;
PETER, JB .
NEW ENGLAND JOURNAL OF MEDICINE, 1975, 292 (07) :344-347
[5]   Incidence of malignant disease in biopsy-proven inflammatory myopathy - A population-based cohort study [J].
Buchbinder, R ;
Forbes, A ;
Hall, S ;
Dennett, X ;
Giles, G .
ANNALS OF INTERNAL MEDICINE, 2001, 134 (12) :1087-1095
[6]   Malignancy in patients with inflammatory myopathy [J].
Buchbinder R. ;
Hill C.L. .
Current Rheumatology Reports, 2002, 4 (5) :415-426
[7]   Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study [J].
Chen, YJ ;
Wu, CY ;
Shen, JL .
BRITISH JOURNAL OF DERMATOLOGY, 2001, 144 (04) :825-831
[8]   The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis [J].
Chinoy, Hector ;
Fertig, Noreen ;
Oddis, Chester V. ;
Ollier, William E. R. ;
Cooper, Robert G. .
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (10) :1345-1349
[9]  
Danko K., 2006, LEGE ARTIS MED, V16, P445
[10]   Paraneoplastic myopathy [J].
Danko, Katalin ;
Ponyi, Andrea ;
Molnar, Andrew P. ;
Andras, Csilla ;
Constantin, Tamas .
CURRENT OPINION IN RHEUMATOLOGY, 2009, 21 (06) :594-598